REFERENCES
- Network A: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the adult respiratory distress syndrome. N Engl J Med. 2000;342:1301–1308.
- Matthay M: Treatment of acute lung injury: clinical and experimental studies. Proc Am Thorac Soc. 2008;5:297–299.
- Calfee C, Matthay M: Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131:913–920.
- Suratt BP: Parsons. Mechanisms of acute lung injury/acute respiratory distress syndrome. Clin Chest Med. 2006;27:579–589.
- Phua J, Badia J, Adhikari N, Friedrich J, Fowler R, Singh J, : Has mortality from acute respiratory distress syndrome decreased over time? Am J Respir Crit Care Med. 2009;179:220–227.
- Suresh G, Soll R: Overview of surfactant replacement trials. J Perinatol. 2005;25:S40–S44.
- Willson D, Thomas N, Markovitz B, Jefferson L, Conaway M, Egan E: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293:470–476.
- Adhikari N, Burns K, Meade M: Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: systematic review and meta-analysis Treat Respir Med. 2004;3:307–328.
- Ware L, Matthay M: The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349.
- Zuo Y, Veldhuizen R, Neumann A, Petersen N, Possmayer F: Current perspectives in pulmonary surfactant—inhibition, enhancement and evaluation. Biochim Biophys Acta. 2008;1778:1947–1977.
- Hallman M, Glumoff V, Rämet M: Surfactant in respiratory distress syndrome and lung injury. Comp Biochem Physiol A Mol Integr Physiol. 2001;129:287–294.
- Hite R, Seeds M, Safta A, Jacinto R, Gyves J, Bass D, Waite B: Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction. Am J Physiol Lung Cell Mol Physiol. 2005;288:L618–L624.
- Furue S, Mikawa K, Nishina K, Shiga M, Ueno M, Tomita Y, : Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med. 2001;29:719–727.
- Attalah H, Wu Y, Alaoui-El-Azher M, Thouron F, Koumanov K, Wolf C, Brochard L, Harf A, Delclaux C, Touqui L: Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J. 2003;21:1040–1045.
- Enhorning G, Shumel B, Keicher L, Sokoloski J, Holm B: Phospholipases introduced into the hypophase affect the surfactant film outlining a bubble. J Appl Physiol. 1992;73:941–945.
- Cockshutt A, Possmayer F: Lysophosphatidylcholine sensitizes lipid extracts of pulmonary surfactant to inhibition by serum proteins. Biochim Biophys Acta. 1991;1086:63–71.
- Zuo Y, Veldhuizen A, Neumann A, Petersen N, Possmayer F: Current pespectives in pulonary suractant-inhibition, enhancement, and evaluation. Biochim Biophys Acta. 2008;1778:1947–1977.
- Wang Z, Chang Y, Schwan A, Notter R: Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs. Am J Respir Cell Mol Biol. 2007;37:387–394.
- Taeusch H, Lu K, Goerke J, Clements J: Nonionic polymers reverse inactivation of surfactant by meconium and other substances. Am J Respir Crit Care Med. 1999;159:1391–1395.
- Lu K, Goerke J, Clements J, Taeusch H: Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium lung injury. Pediatr Res. 2005;58:206–210.
- Sahu S, Tanswell A, Lynn W: Isolation and characterization of glycosaminoglycans secreted by human foetal lung type II pneumocytes in culture. J Cell Sci. 1980;42:183–188.
- Skinner S, Post M, Torday J, Stiles A, Smith B: Characterization of proteoglycans synthesized by fetal rat lung type II pneumonocytes in vitro and the effects of cortisol. Exp Lung Res. 1987;12:253–264.
- Lu K, Goerke J, Clements J, Taeusch H: Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res. 2005;57:237–241.
- Nitzan D, Nitzan U, Dan P, Yedgar S: The role of hyaluronic acid in protecting surface-active phospholipids from lysis by exogenous phospholipase A2. Rheumatology. 2001;40:336–340.
- Putz G, Goerke J, Taeusch W, Clements J: Comparison of captive and modified pulsating bubble surfactometers. J Appl Physiol. 1994;76:1425–1431.
- Seurynck S, Brown N, Wu C, Germino K, Kohlmeir E, Ingenito E, Glucksberg M, Barron A, Johnson M: Optical monitoring of bubble size and shape in a pulsating bubble surfactometer. J Appl Physiol. 2005;99:624–633.
- Yu S, Possmayer F: Role of bovine pulmonary surfactant-associated proteins in the surface-active property of phospholipid mixtures. Biochim Biophys Acta. 1990;1046:233–241.
- Bray BA: The role of hyaluronan in the pulmonary alveolus. J Theor Biol. 2001;210:121–130.
- Diemel R, Haagsman H, Putz G: In vitro and in vivo intrapulmonary distribution of fluorescent labelled surfactant. Crit Care Med. 2002;30:1083–1090.
- Taeusch H, de la Sena J, Perez-Gil J, Alonso C, Zasadzinski J: Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: experimental. Biophys J. 2005;89:1769–1779.
- Kitsiouli E, Nakos G, Lekka M: Differential determination of phospholipase A(2) and PAF-acetylhydrolase in biological fluids using fluorescent substrates. J Lipid Res. 1999;40:2346–2356.
- Attalah H, Wu Y, Alaoui-El-Azher M, Thouron F, Koumanov K, Wolf C, Brochard L, Harf A, Delclaux C, Touqui L: Induction of type-IIA secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J. 2003;21:1040–1045.
- Lu K, Perez-Gil J, Taeusch HW: Kinematic viscosities of surfactants with added polymers. Biochim Biophys Acta. 2009;1788:632–637.
- Hite R, Seeds M, Jacinto R, Grier B, Waite B, Bass D: Lysophospholipid and fatty acid inhibition of pulmonary surfactant: non-enzymatic models of phospholipase A2 surfactant hydrolysis. Biochim Biophys Acta. 2005;1720:14–21.
- Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, : Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by direct surfactant protein A-phospholipase A2 protein interaction. J Clin Investig. 1998;102:1152–1160.
- Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka MG: Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med. 2005;33:772–779.
- Baue A: MOF, MODS, and SIRS: what is in a name or an acronym? Shock. 2006;26:438–449.
- Bowton D, Dmitrienko A, Israel E, Zeiher B, Sides CD: Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J Asthma. 2005;42:65–71.
- Wheeler D: Phospholipase A2 and acute lung injury: it's just not that simple. Crit Care Med. 2008;33:904–905.
- Liu Y, Lee C, Dedaj R, Zhao H, Mrabat H, Sheidlin A, : High-molecular-weight hyaluronan—a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Crit Care. 2008;12(4):R102.
- Turino G, Cantor J: Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med. 2003;167:1169–1175.
- Taeusch H, Dybbro E, Lu K: Pulmonary surfactant adsorption is increased by hyaluronan or polyethylene glycol. Colloids Surf B Biointerfaces. 2008;162:243–249.
- Lu K, Taeusch H, Robertson B, Goerke J, Clements J: 2000. Polymer-surfactant treatment of meconium-induced acute lung injury. Am J Respir Crit Care Med. 2000;162:623–628.
- Cantor J, Nadkarni P: Hyaluronan: the Jekyll and Hyde molecule. Inflamm Allergy Drug Targets. 2006;5:257–260.